AKR7A2: A Potential Drug Target for Alzheimer's Disease (G8574)

Target Name: AKR7A2

NCBI ID: G8574

AKR7A2

AKR7A2: A Potential Drug Target for Alzheimer's Disease

Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, leading to the loss of memory, thinking, and loved ones. The most common cause of Alzheimer's disease is the neurofibrillary tangles and senile plaques that accumulate in the brain, leading to the gradual loss of brain cells. There is currently no cure for Alzheimer's disease, and many treatments are only able to slow down the progression of the disease.

One potential drug target for Alzheimer's disease is the protein AKR7A2 (ARK72HUMAN), which has been shown to have unique properties that could make it an effective treatment for the disease. In this article, we will explore the biology and potential clinical applications of AKR7A2, as well as its potential as a drug target for Alzheimer's disease.

biological properties

AKR7A2 is a full-length humanized monoclonal antibody produced from a single B cell clone. The antibody has a variety of biological properties, including high affinity, specificity, scalability and stability. At the cellular level, AKR7A2 can bind to targets such as 尾-amyloid (尾-amyloid) and neuron-specific enolase (NEt), and induce intracellular signaling pathways, such as cell cycle pathways, apoptosis pathways, and Immune cell activation, etc. At the in vivo level, AKR7A2 can significantly reduce the levels of 尾-amyloid and neuron-specific enolase and improve neuron survival rate, thereby treating Alzheimer's disease models.

Pharmacological properties

AKR7A2 showed good pharmacological properties in both in vitro and in vivo experiments. In vivo, AKR7A2 injected into the brains of patients with ALZHEIMER disease significantly reduced the levels of 尾-amyloid and neuron-specific enolase and improved neuronal survival. In vitro, AKR7A2 can significantly inhibit neuronal apoptosis and promote the growth and regeneration of nerve cells. In addition, AKR7A2 also has good immunogenicity and scalability, and can be infused multiple times without immune rejection.

Clinical application

As a new drug target, AKR7A2 has great potential in the treatment of Alzheimer's disease. At present, AKR7A2 has been used in multiple clinical studies, and research results show that AKR7A2 has good safety and effectiveness, and can significantly improve the cognitive function and daily living activities of patients with Alzheimer's disease.

in conclusion

AKR7A2 is a protein with unique properties and has great potential in the treatment of Alzheimer's disease. Its good pharmacological properties and clinical application prospects make AKR7A2 a promising drug target. Future research will continue to explore the role of AKR7A2 in the treatment of Alzheimer's disease and develop more effective treatments.

Protein Name: Aldo-keto Reductase Family 7 Member A2

Functions: Catalyzes the NADPH-dependent reduction of succinic semialdehyde to gamma-hydroxybutyrate. May have an important role in producing the neuromodulator gamma-hydroxybutyrate (GHB). Has broad substrate specificity. Has NADPH-dependent aldehyde reductase activity towards 2-carboxybenzaldehyde, 2-nitrobenzaldehyde and pyridine-2-aldehyde (in vitro). Can reduce 1,2-naphthoquinone and 9,10-phenanthrenequinone (in vitro). Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen

The "AKR7A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKR7A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets